Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy? Alberto Bossi  European Urology Supplements  Volume 8, Issue 12, Pages 848-851 (December 2009) DOI: 10.1016/j.eursup.2009.09.003 Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 1 Ten-year results of the European Organisation for Research and Treatment of Cancer 22861 trial comparing long-term adjuvant hormone therapy plus radiation therapy (RT) with RT alone in patients with locally advanced prostate cancer [10]. OS=overall survival; RT=radiation therapy; HT=hormone therapy. European Urology Supplements 2009 8, 848-851DOI: (10.1016/j.eursup.2009.09.003) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 2 The effect of 3 mo versus 8 mo of neoadjuvant hormone therapy to radiation therapy in patients with clinically localised prostate cancer enrolled in a Canadian multicentre, randomised, controlled phase 3 trial [14]. HT=hormone therapy; RT=radiation therapy; DFS=disease-free survival. European Urology Supplements 2009 8, 848-851DOI: (10.1016/j.eursup.2009.09.003) Copyright © 2009 European Association of Urology Terms and Conditions